Doomsday Beans and Biotech

AI meets the Mayan Calendar July 11, 2024 [WEBSITE]( | [UNSUBSCRIBE]( Awaiting doomsday? Here’s one way to hedge your “beans in the bunker” portfolio. Doomsday Beans and Biotech CHRIS CAMPBELL Dear Reader, The year was 2012. The much-anticipated apocalypse, as forecasted by some readings of the Mayan Calendar, did not come to pass. For better or worse. So, of course, we all had to awkwardly slink back to work on January 1st and apologize to our bosses. (Or was that just me?) Instead, something even more unexpected happened: a revolution in medicine began. While preppers were busy stockpiling doomsday beans… Emily Whitehead was undergoing a revolutionary biotech treatment. You might recall the story. Emily was only six when diagnosed with acute lymphoblastic leukemia (ALL). After her parents tried all the go-to treatments and ran out of options, they took a leap of faith with an experimental therapy - CAR-T cell therapy. The story goes like this: T-cells, the immune system’s foot soldiers, are always on the lookout for intruders. Normally, they’re pretty good at their job. But cancer cells are sneaky. Like a politician during a budget crisis, they hide, they disguise themselves. They evolve. So, scientists asked, what if we could give these T-cells a new set of eyes… a way to spot cancer no matter how well it hides? That’s where the “chimeric antigen receptor,” or CAR, comes in. Scientists take a patient’s T-cells and send them to boot camp in the lab. There, they’re “trained” to express CARs, which are like high-tech surveillance equipment. Putting it plainly: Doctors took Emily’s T-cells, equipped them with special “find and destroy” orders for cancer cells, and sent them back into her body. And guess what? Within weeks, Emily’s leukemia was in full retreat. She became the first pediatric patient to be saved by this groundbreaking therapy. Her story gained worldwide attention and has been featured in various media outlets, including a documentary called Cancer: The Emperor of All Maladies. And so far so good. Alas, there’s a catch: CAR-T therapy isn’t perfect. It can cause severe side effects, like cytokine release syndrome, where the immune system goes into overdrive, leading to high fever and inflammation. If chemotherapy is like using a sledgehammer to fix a watch… Then CAR-T is like using a flamethrower to take out a mosquito - effective, yes, but also potentially hazardous. And then there’s the cost. From snout to tail, CAR-T therapy can cost up to $1 million per patient, putting it well out of reach for the many. Fast forward to today… We’re riding the wave of another medical revolution - this time fueled by artificial intelligence. Are You Positioned for AI’s Big Upgrade? OpenAI is gearing up to launch a big AI upgrade on July 31st… One that will push AI technology as we know it into a brand new era. The gains from this new window will eclipse anything we've seen over the past two years with AI... And we want you to take full advantage of it. [Go here now for the key information you need to position yourself for the AI wealth window’s final chapter.]( Super Molecule Shufflers As you read this, AI-driven platforms are supercharging their abilities to design custom drugs at unprecedented speeds and cost. Take the case of a recent patient with a rare form of cystic fibrosis. By decoding the patient’s genetic quirks, AI quickly pinpointed a promising molecule, which then passed preclinical tests with flying colors. Boom. A process that used to take years now took mere months. Moreover, AI can help determine the optimal dosage for each patient, reducing the risk of adverse reactions and the costs associated with treating those reactions To be sure, the implications of programmable personalized medicine extend beyond rare diseases. For common conditions like cancer, diabetes, and heart disease, AI can help identify which treatments are most likely to be effective for different patient subgroups - all based on their genetic makeup, lifestyle, and environmental factors. This precision medicine approach not only improves outcomes but also reduces the trial-and-error aspect of treatment. This is the promise of programmable personalized medicine: leveraging advanced tech to decode biology and deliver the best possible therapies, quickly and affordably. All that’s to say… If you’re still stocking up on beans, waiting for the world to end… Perhaps you should hedge your bets and stock up on some biotech, too. But that’s just ONE of many sectors our Paradigm researchers are digging into in the AI space. If you’re a Paradigm Mastermind Group member, you have the “insider scoop.” Still not a member? No worries. This week, in a rare interview, James popped the lid open on the truth about the AI industry - and how to profit: [Here’s what they know.]( Until tomorrow, Chris Campbell For Altucher Confidential Rate this email Like Dislike Thanks for rating this content! Looks like something went wrong. Please try to rate again. Congrats, you earned this… As one of my readers, you qualify for [this special deal.]( Only a small fraction of our readers will have the chance to see this. Fortunately, you’re one of them. All you have to do is [click here now to see how to claim your special deal.]( You Might be Interested in... [Jim Rickards: Demflation Will Kill The Middle Class]( [Wall Street charging after THIS 15.7 trillion opportunity]( [TikTok Takeover!]( ☰ ⊗ [ARCHIVE]( [ABOUT]( [Contact Us]( © 2024 Paradigm Press, LLC. 1001 Cathedral Street, Baltimore, MD 21201. By submitting your email address, you consent to Paradigm Press, LLC. delivering daily email issues and advertisements. To end your Altucher Confidential e-mail subscription and associated external offers sent from Altucher Confidential, feel free to [click here.]( Please note: the mailbox associated with this email address is not monitored, so do not reply to this message. We welcome comments or suggestions at feedback@altucherconfidential.com. This address is for feedback only. For questions about your account or to speak with customer service, [contact us here]( or call (844)-731-0984. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Altucher Confidential is committed to protecting and respecting your privacy. We do not rent or share your email address. Please read our [Privacy Statement.]( If you are having trouble receiving your Altucher Confidential subscription, you can ensure its arrival in your mailbox by [whitelisting Altucher Confidential.](